For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...

However, it may cover Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and can help manage treatment-resistant depression. Despite not yet having FDA ...

Ketamine is an old anesthesia drug with psychedelic qualities, and it has been getting a lot of attention for its ability to ...

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Note: I do not provide IV Ketamine. I am a provider of INharmony ... treatment using Transcranial Magnetic Stimulation (TMS) and Esketamine Treatment at Greenbrook Neurohealth Center in Charlotte ...